Thomas F. Kearns, Jr. Sells 18,000 Shares of FibroGen, Inc (FGEN) Stock

FibroGen, Inc (NASDAQ:FGEN) Director Thomas F. Kearns, Jr. sold 18,000 shares of the stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $45.22, for a total transaction of $813,960.00. Following the sale, the director now owns 156,564 shares in the company, valued at approximately $7,079,824.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of FibroGen, Inc (NASDAQ FGEN) traded down $0.23 during mid-day trading on Friday, reaching $46.87. 485,681 shares of the company traded hands, compared to its average volume of 629,353. FibroGen, Inc has a 52 week low of $19.25 and a 52 week high of $60.15. The company has a debt-to-equity ratio of 0.16, a quick ratio of 10.83 and a current ratio of 10.83.

ILLEGAL ACTIVITY WARNING: This article was first published by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.truebluetribune.com/2017/11/17/thomas-f-kearns-jr-sells-18000-shares-of-fibrogen-inc-fgen-stock.html.

A number of hedge funds have recently modified their holdings of the stock. Iguana Healthcare Management LLC purchased a new stake in FibroGen in the third quarter worth approximately $2,152,000. California Public Employees Retirement System boosted its holdings in FibroGen by 1.8% in the third quarter. California Public Employees Retirement System now owns 94,900 shares of the biopharmaceutical company’s stock worth $5,106,000 after purchasing an additional 1,700 shares during the last quarter. Perceptive Advisors LLC purchased a new stake in FibroGen in the third quarter worth approximately $462,000. Jane Street Group LLC boosted its holdings in FibroGen by 102.4% in the third quarter. Jane Street Group LLC now owns 17,613 shares of the biopharmaceutical company’s stock worth $948,000 after purchasing an additional 8,910 shares during the last quarter. Finally, BBR Partners LLC purchased a new stake in FibroGen in the third quarter worth approximately $299,000. Institutional investors own 46.93% of the company’s stock.

A number of equities research analysts have recently commented on the stock. Leerink Swann reiterated an “outperform” rating and set a $82.00 price target (up previously from $52.00) on shares of FibroGen in a report on Tuesday, August 8th. William Blair reiterated an “outperform” rating on shares of FibroGen in a report on Wednesday, August 9th. Jefferies Group LLC reiterated a “buy” rating and set a $75.00 price target on shares of FibroGen in a report on Tuesday, August 8th. Citigroup Inc. increased their price target on shares of FibroGen from $48.00 to $65.00 and gave the company a “top pick” rating in a report on Tuesday, August 8th. Finally, Mizuho reiterated a “hold” rating and set a $61.00 price target on shares of FibroGen in a report on Thursday, November 9th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. FibroGen presently has a consensus rating of “Buy” and an average price target of $65.67.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply